-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with a poor prognosis; Treatment options are extremely limited
This is a multicenter, phase 2 trial that enrolled adults with relapsed/refractory ATL and treated with Valemetostat (200 mg/day) until disease progression or intolerable toxicity develops
A total of 25 patients (median age 69.
Adverse reactions requiring urgent treatment (TEAE) are manageable
In summary, Valemetostat has demonstrated good efficacy and tolerability in patients with relapsed/refractory adult T-cell leukemia/lymphoma who have previously been treated with multiple lines, and further research
Original Source:
Koji Izutsu, et al.